Efficacy Testing as a Primary Purpose of Phase 1 Clinical Trials: Is it Applicable to First-in-Human Bionics and Optogenetics Trials?

American Journal of Bioethics Neuroscience 3 (2):20-22 (2012)
  Copy   BIBTEX

Abstract

In her article, Pascale Hess raises the issue of whether her proposed model may be extrapolated and applied to clinical research fields other than stem cell-based interventions in the brain (SCBI-B) (Hess 2012). Broadly summarized, Hess’s model suggests prioritizing efficacy over safety in phase 1 trials involving irreversible interventions in the brain, when clinical criteria meet the appropriate population suffering from “degenerative brain diseases” (Hess 2012). Although there is a need to reconsider the traditional phase 1 model, especially with respect to first-in-human clinical trials involving novel technologies, the question arises as to whether it is appropriate to advocate for a new model that prioritizes efficacy over safety across all phase 1 clinical research trials involving irreversible interventions in the brain.

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 94,452

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Translating Stem Cell Research: Challenges at the Research Frontier.David Magnus - 2010 - Journal of Law, Medicine and Ethics 38 (2):267-276.
Hollow Hunt for Harms.Jacob Stegenga - 2016 - Perspectives on Science 24 (5):481-504.

Analytics

Added to PP
2012-10-10

Downloads
34 (#466,656)

6 months
8 (#528,674)

Historical graph of downloads
How can I increase my downloads?

Author Profiles

Fred Gilbert
University of Tasmania
Alexander Harris
McMaster University